Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY Keytruda/Ibrance Added to Pilot CEA Drug List, but There Won’t Be Price Tweaks
June 14, 2018
-
REGULATORY Japan’s 1st Conditional OK Might Come This Autumn for Pfizer’s Next-Gen ALK Inhibitor Lorlatinib
June 13, 2018
-
REGULATORY PMDA to Promote Development of Next-Generation Drugs by Improving Its Science Level in Drug Evaluation
June 13, 2018
-
BUSINESS Angry Shareholders Say Don’t Make Takeda a Debt-Saddled Company
June 12, 2018
-
REGULATORY MHLW Panel Gives Thumbs-Up for Entyvio, Official Nod Expected This Month
June 11, 2018
-
BUSINESS Bayer Establishes Asia’s 1st “CoLaborator” in Kobe for Use by Startups
June 8, 2018
-
REGULATORY AMED Discloses Individual R&D Project Funding; 31 Receive Funding of Over 1 Billion Yen
June 7, 2018
-
REGULATORY Japan Eyes Economic Assessments for New Drug Listing: Draft Honebuto Paper
June 6, 2018
-
ACADEMIA MHLW Study Group to Discuss Roles of JAK Inhibitors and Biosimilars toward RA Treatment Guidelines Revision
June 5, 2018
-
BUSINESS FY2017 Earnings Roundup - 2: Global Brands Gaining Further Traction, Some Notch Better-than-Expected Growth
June 5, 2018
-
BUSINESS FY2017 Earnings Roundup - 1: Major Japan Makers Braced for Gloomier Year Ahead at Home, See 4.4% Dip
June 4, 2018
-
BUSINESS Japan Drug Makers See Rising Overseas Sales Ratio amid Uphill Battle at Home: Tally
June 1, 2018
-
TRENDS Drug Maker Downsizing Shows No Sign of Stopping; Boehringer to Ax 300 Jobs, while Shionogi Sees “Tremendous Reduction” in Rep Numbers
May 31, 2018
-
REGULATORY Japan’s First Biosimilars for Enbrel, Herceptin Added to NHI Price List
May 30, 2018
-
BUSINESS Perspective on Takeda/Shire Deal - 1: Profits Delivered by On-Market Products More Important than Pipeline
May 29, 2018
-
REGULATORY Takeda’s Entyvio Up for MHLW Panel Review on June 8
May 28, 2018
-
BUSINESS 3 Generic Major Companies Maintain Double-Digit Growth in FY2017: Jiho Tally
May 28, 2018
-
REGULATORY MOF Pitching 2-Step Drug Price Tweaks in 2019 Tax Hike Year
May 25, 2018
-
ORGANIZATION Isao Teshirogi Elected New FPMAJ Chairman
May 25, 2018
-
REGULATORY PMDA, FDA Team Up to Help Developing Countries to Facilitate Pediatric Drug Development
May 24, 2018
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…